Patrys’s technology brings together all the advantages of antibodies—including specificity and safety—with those of DDR therapies, such as PARP inhibitors, that target DDR deficiencies ...

Clovis Oncology, Pfizer, and GlaxoSmithKline have also marketed rival PARP drugs, with the latter ... have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2 ...

Topline results from the Chinese portion of the trial for the antibody-drug conjugate (ADC) TIVDAK support the company’s ...

Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.